| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Bezlotoxumab |
| Brand | Zinplava® |
| Indication | Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. |
| Assessment Process | |
| Rapid review commissioned | 11/05/2017 |
| Rapid review completed | 14/06/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 14/06/2017 |
The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.